A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.

MLA

Ito, Mototsugu, et al. “A Phase 1b Study to Investigate the Potential Interactions between ASP8062 and Buprenorphine/Naloxone in Patients with Opioid Use Disorder.” Journal of Psychopharmacology, vol. 37, no. 2, Feb. 2023, pp. 144–54. EBSCOhost, https://doi.org/10.1177/02698811221149657.

APA

Ito, M., Walzer, M., Beth Blauwet, M., Spence, A., Heo, N., Kelsh, D., Blahunka, P., Erdman, J., Nour Alsharif, M., & Marek, G. J. (2023). A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder. Journal of Psychopharmacology, 37(2), 144–154. https://doi.org/10.1177/02698811221149657

Chicago

Ito, Mototsugu, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Debra Kelsh, Paul Blahunka, Jay Erdman, Mohamad Nour Alsharif, and Gerard J Marek. 2023. “A Phase 1b Study to Investigate the Potential Interactions between ASP8062 and Buprenorphine/Naloxone in Patients with Opioid Use Disorder.” Journal of Psychopharmacology 37 (2): 144–54. doi:10.1177/02698811221149657.